CureDuchenne Partners with Baebies for Duchenne Screening

A University of Hartford alumnus, Jeffrey Goffman is an accomplished healthcare executive who has served in various leadership roles over the past two-plus decades. In his current position, Jeffrey Goffman serves as the board chairman for CureDuchenne International, an organization devoted to finding new treatments and a cure for Duchenne muscular dystrophy.

In October 2018, CureDuchenne entered into a partnership with startup Baebies, a company that specializes in providing screening services for infants and children. CureDuchenne’s three-year investment in the startup will enable Baebies to add Duchenne muscular dystrophy to the list of conditions detected using its newborn screening technology. Duchenne is the most widespread and lethal form of the disease and primarily is present in young boys.

Screening for Duchenne is vital for early detection of the disease. With an early diagnosis, parents have more treatment options available to them, including cutting-edge clinical research trials. More widespread screening also provides valuable data to researchers who are trying to learn more about the incidence rate and any genetic indicators that may be linked with Duchenne. To learn more about CureDuchenne and its partnerships, visit cureduchenne.org.